Robert Cyran and Richard Beales examine why the failure of tests for a single drug caused Alnylam Pharmaceuticals to lose half its $6 bln market capitalization overnight.
Source: top Video
Your email address will not be published. Required fields are marked *
Current ye@r *
Leave this field empty
© Copyright 2015, Big Board Alerts
Designed & Developed by: Netleon Technologies